Should healthcare bodies asses new drugs and medical equipment based on the effect and isolated costs of the products? Or should they take secondary effects, such as the number of days a patient does not have to spend in a costly hospital bed, into consideration as well? Or the value a depressive individual could give back to society, if the proper medicine gets that person off of government benefits?
The life science industry has been a long time advocate of the world’s healthcare bodies adapting a more holistic outlook on healthcare expenditure, and public bodies are beginning to take notice and adopt this type of thinking.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app